ESR1 and breast carcinoma: Our study examined the adjuvant systemic therapy prescribing patterns and distant recurrence rates for ER+/HER2− nonmetastatic breast cancer patients in a multidisciplinary Australian institutional setting based on the Oncotype DX recurrence risk groups.